1.Effect of Pyrroloquinoline Quinone on Aging of Rat Hippocampal Neurons in Vitro
Xiwen TONG ; Yanmei HAN ; Yonghui DENG ; Hui SHEN ; Shunhua XIONG
Chinese Journal of Rehabilitation Theory and Practice 2008;14(9):804-805
Objective To investigate the effect of pyrroloquinoline quinone(PQQ) on the aging of rat hippocampal neurons induced by D-galactose(D-gal).Methods Hippocampal neurons were cultured in vitro.The aging of the hippocampal neurons was induced by high dose D-gal,PQQ protection were used 30 min before D-gal.The metamorphosis of hippocampal neurons was observed under the microscope.The contents of free radical was measured.The incidence of apoptosis of hippocampus cells was tested with the flow cytometry.The expression of Bax was detected with immunohistochemical staining.Results After the cells cultured in vitro exposed to D-gal,the content of free radical and the expression of Bax of the hippocampal neurons increased.After pretreatment of the cultured neurons with PQQ,the contents of free radical and the expression of Bax decreased,the survival of hippocampal neurons increased.Conclusion PQQ may slow the aging progress of hippocamal neurons induced by D-gal.
2.Equivalence comparison between domestic and imported clopidogrel for percutaneous coronary interventions in 1 798 cases
Yuheng YANG ; Zhonghua SUN ; Jie MI ; Minghui ZHONG ; Jian ZHANG ; Yongde WANG ; Tao CHEN ; Gang TIAN ; Xiwen ZANG ; Guojun XIONG ; Huan LUO ; Xiangqian QI
Chinese Journal of Tissue Engineering Research 2013;(47):8175-8181
BACKGROUND:A few of studies have showed similar efficacy and safety between domestic clopidogrel (Talcom?) and imported clopidogrel (Plavix?) in patients after percutaneous coronary intervention, but there is lack of large-scale, large sample, and prospective clinical comparative study in China.
OBJECTIVE:To compare the efficacy and safety of Talcom?and Plavix?on percutaneous coronary intervention.
METHODS:Total y 1 798 patients with Coronary atherosclerotic heart disease who received percutaneous coronary interventions were divided to two groups:Talcom?group (n=1 104) and Plavix?group (n=694). 300 mg clopidogrel was administrated oral y before percutaneous coronary intervention fol owed by 75 mg/d clopidogrel sequential y for 1 year. Al the patients were fol owed for 3-28 months to observe the incidence rate of stent thrombosis at acute, subacute, late, and very late stage, major adverse cardiac events of combination end point (including myocardial infarction, cardiac death, and stroke), and correlated adverse reactions, such as bleeding.
RESULTS AND CONCLUSION:There were no significant differences in the incidence of stent thrombosis, target vessel revascularization, cardiac death, bleeding, major bleeding and major adverse cardiac events of combination end point between Talcom?group and Plavix?group. In addition, event-free survival also showed no difference between the two groups. After treatment, white blood cellcount, erythrocyte count, hemoglobin, hematocrit, platelet count were significantly decreased in both the two groups (P<0.05). Hemoglobin level in the Talcom?group was fewer than that in the Plavix?group (P<0.05). The results suggest that effects and safety of Talcom?are similar to those of Plavix?for percutaneous coronary interventions.
3.Mitochondrial protein IF1 is a potential regulator of glucagon-like peptide (GLP-1) secretion function of the mouse intestine.
Ying WANG ; Jiaojiao ZHANG ; Xinyu CAO ; Yaya GUAN ; Shuang SHEN ; Genshen ZHONG ; Xiwen XIONG ; Yanhong XU ; Xiaoying ZHANG ; Hui WANG ; Jianping YE
Acta Pharmaceutica Sinica B 2021;11(6):1568-1577
IF1 (ATPIF1) is a nuclear DNA-encoded mitochondrial protein whose activity is inhibition of the F